Black Diamond Therapeutics Inc (BDTX) — Cash Flow Reinvestment Rate

Latest as of March 2025: 0.16x

Black Diamond Therapeutics Inc (BDTX) has a Cash Flow Reinvestment Rate of 0.16x as of March 2025, reinvesting $8.55 Million (capex $0.00 plus investments $8.55 Million) from operating cash flow of $53.41 Million. Check BDTX cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.16x
(Capex + Investments) / Operating CF

Total Reinvested

$8.55 Million
Capex + Investments

Operating Cash Flow

$53.41 Million
USD

Capital Expenditures

$0.00
USD

Black Diamond Therapeutics Inc Cash Flow Reinvestment Rate (2025–2025)

Historical reinvestment intensity for Black Diamond Therapeutics Inc across 1 annual periods. Explore BDTX long-term investment intensity to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Black Diamond Therapeutics Inc (2025–2025)

Year-by-year capital reinvestment analysis for Black Diamond Therapeutics Inc. For live market cap and broader valuation context, see Black Diamond Therapeutics Inc (BDTX) market capitalisation.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2025 1.52x $44.93 Million $29.61 Million $0.00
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow